Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Ben Tran; Lisa Horvath; Tanya B Dorff; Richard Greil; Jean-Pascal H Machiels; Felicia Roncolato; Karen A Autio; Matthew Rettig; Karim Fizazi; Martijn P Lolkema; Anthony C Fermin; Mark Salvati; Hosein Kouros-Mehr

Conference Proceedings

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

Ben Tran, Lisa Horvath, Tanya B Dorff, Richard Greil, Jean-Pascal H Machiels, Felicia Roncolato, Karen A Autio, Matthew Rettig, Karim Fizazi, Martijn P Lolkema, Anthony C Fermin, Mark Salvati, Hosein Kouros-Mehr

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2020

DOI: 10.1200/jco.2020.38.6_suppl.tps261

University of Melbourne Researchers

Ben Tran Author The Sir Peter MacCallum Department of Oncology

Grants

Funding Acknowledgements

Amgen Inc.

Citation metrics

2Web of Science

4Dimensions

Keywords

Life Sciences & Biomedicine

Oncology

Science & Technology

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

University of Melbourne Researchers

Grants

Funding Acknowledgements

Citation metrics

Keywords

STUDY AT MELBOURNE

ABOUT US

CONTACT & MAPS

ALUMNI & FRIENDS

RESEARCH

ENGAGEMENT